RxDoctor Payments Data

Miguel Gonzalez, MD

Internal Medicine · Leesburg, FLNPI 1750333480

Payments from drug & device makers

$1,504in general payments, 2019–2025

Across 64 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$388
  • Exact Sciences$194
  • Novo Nordisk$176
  • AstraZeneca$174
  • Hydrocision, Inc.$106
  • Shield Therapeutics Inc$86
  • plus $381 from 13 others

What the payments were for

  • Food & beverage$1,49199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,504 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$50,396
Medicare patients
185
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$39,329
EliquisApixaban24$35,150
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$19,049
Rosuvastatin Calcium153$2,217
Albuterol Sulfate HfaAlbuterol Sulfate52$1,697
Atorvastatin Calcium129$1,577
Ezetimibe28$1,403
Gabapentin56$1,337
Metoprolol Succinate102$1,246
Amlodipine Besylate214$1,236
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide62$1,068
Levothyroxine Sodium107$1,068
Celecoxib12$901
Omeprazole43$858
Losartan Potassium88$735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$39,32926 claims
GSKTrelegy Ellipta$388$19,04912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Leesburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →